Liu Yong-Xuan, Wang Xin-Shuai, Wang Yu-Feng, Hu Xiao-Chen, Yan Jun-Qiang, Zhang Ya-Li, Wang Wei, Yang Rui-Jie, Feng Ying-Ying, Gao She-Gan, Feng Xiao-Shan
Department of Oncology, Cancer Institute, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, People's Republic of China.
Onco Targets Ther. 2016 May 4;9:2649-54. doi: 10.2147/OTT.S102616. eCollection 2016.
The overexpression of programmed cell death-ligand 1(PD-L1) has been observed in gastric cancer (GC). However, whether the expression of PD-L1 in tumor cells or blood serum is associated with the prognosis of patients with GC remains unclear. Therefore, we performed a meta-analysis to evaluate the prognostic significance of PD-L1 expression in GC. Electronic databases were searched systematically. Studies that met the inclusion criteria were included in the meta-analysis. Data concerning the hazard ratio (HR) for overall survival and disease-free survival with a 95% confidence interval (CI) according to the expression status of PD-L1 evaluated by immunohistochemistry or enzyme-linked immunosorbent assay were extracted. The data were analyzed using a random effects model. Subgroup analyses were proposed. Our results showed that eight studies with 950 patients met the inclusion criteria and were included in the meta-analysis. The pooled HR for overall survival indicated that patients with PD-L1-positive expression had significantly shorter survival time compared with the PD-L1-negative group (HR 1.60, 95% CI 1.09-2.36, P=0.012). The pooled HR for disease-free survival demonstrated that the difference between the two groups was not statistically significant (HR 1.02, 95% CI 0.32-3.20, P=0.98). In conclusion, our results indicate that the evaluation of PD-L1 overexpression in GC tissue or blood serum may be useful in the future as a novel prognostic factor.
在胃癌(GC)中已观察到程序性细胞死亡配体1(PD-L1)的过表达。然而,肿瘤细胞或血清中PD-L1的表达是否与GC患者的预后相关仍不清楚。因此,我们进行了一项荟萃分析,以评估PD-L1表达在GC中的预后意义。系统检索了电子数据库。符合纳入标准的研究被纳入荟萃分析。提取了根据免疫组织化学或酶联免疫吸附测定评估的PD-L1表达状态,关于总生存和无病生存的风险比(HR)及95%置信区间(CI)的数据。使用随机效应模型对数据进行分析。提出了亚组分析。我们的结果显示,八项研究共950例患者符合纳入标准并被纳入荟萃分析。总生存的合并HR表明,与PD-L1阴性组相比,PD-L1阳性表达的患者生存时间显著缩短(HR 1.60,95%CI 1.09-2.36,P = 0.012)。无病生存的合并HR表明,两组之间的差异无统计学意义(HR 1.02,95%CI 0.32-3.20,P = 0.98)。总之,我们的结果表明,评估GC组织或血清中PD-L1过表达作为一种新的预后因素在未来可能有用。